Feasibility of Distinguishing Performance Among Provider Groups Using Patient-reported Outcome Measures in Older Adults With Multiple Chronic Conditions.


Journal

Medical care
ISSN: 1537-1948
Titre abrégé: Med Care
Pays: United States
ID NLM: 0230027

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 14 11 2018
medline: 14 6 2019
entrez: 14 11 2018
Statut: ppublish

Résumé

To examine minimum sample sizes and follow-up times required for patient-reported outcome-based performance measures (PMs) to achieve acceptable reliability as PMs. We used 2 groups of patients age 65+ with at least 2 of 13 chronic conditions. The first was a sample of Medicare Advantage beneficiaries, who reported health-related quality of life (HRQoL) at baseline and 2 years. The second was a sample of primary care patients, who reported HRQoL at baseline and 6 months. Medicare Advantage beneficiaries completed the Veterans RAND 12-Item Short Form (VR-12), while the primary care sample completed the Patient-Reported Outcomes Measurement Information System 29-Item Profile Measure (PROMIS-29). We constructed binary candidate PMs indicating stable or improved physical or mental HRQoL at follow-up, and continuous PMs measuring mean change over time. In the Medicare Advantage sample, with a sample size per entity profiled of 160, the most promising PM achieved a reliability of 0.32 as a PM. A sample size of 882 per entity would have been needed for this PM to achieve an acceptable reliability of 0.7. In the prospective sample, with a sample size of 27 per clinic, the most promising PM achieved a reliability of 0.16 as a PM. A sample size of 341 patients (at the clinic level) would have been needed for this PM to achieve a reliability of 0.7. Achieving acceptable reliability for these PMs and conditions would have required minimum sample sizes of 341 at the clinic level or 880 at the health plan level. These estimates can guide the design of future patient-reported outcome-based PMs.

Identifiants

pubmed: 30422839
doi: 10.1097/MLR.0000000000001013
pmc: PMC6375799
mid: NIHMS1509877
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

180-186

Subventions

Organisme : NIDA NIH HHS
ID : HHSN271201500064C
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

JAMA. 1999 Jun 9;281(22):2098-105
pubmed: 10367820
Qual Life Res. 2014 Jun;23(5):1579-91
pubmed: 24318083
J Palliat Med. 2018 Jul;21(7):924-932
pubmed: 29649404
Pancreas. 2012 Apr;41(3):461-6
pubmed: 22422138
Support Care Cancer. 2016 Sep;24(9):3695-703
pubmed: 27029477
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Arch Phys Med Rehabil. 2009 Mar;90(3):420-8
pubmed: 19254606
Ann Thorac Surg. 2013 Jun;95(6):1946-51
pubmed: 23453761
Value Health. 2014 Dec;17(8):846-53
pubmed: 25498780
Complement Ther Clin Pract. 2016 May;23:110-6
pubmed: 25990687
Clin Rheumatol. 2017 Mar;36(3):555-562
pubmed: 27848056
Med Care. 2011 Feb;49(2):126-31
pubmed: 20421826
AIDS Patient Care STDS. 2017 Feb;31(2):43-48
pubmed: 28051875
Inflamm Bowel Dis. 2017 May;23(5):798-803
pubmed: 28301432
Rehabil Psychol. 2017 Aug;62(3):401-406
pubmed: 28581321
J Am Coll Cardiol. 2000 Apr;35(5):1245-55
pubmed: 10758967
Arthritis Care Res (Hoboken). 2011 Nov;63(11):1620-8
pubmed: 22034123
Qual Life Res. 2018 Jul;27(7):1885-1891
pubmed: 29569016
J Gen Intern Med. 2016 Aug;31(8):840-5
pubmed: 27197975
JAMA. 1989 Aug 18;262(7):925-30
pubmed: 2754793
J Orthop Res. 2018 Apr;36(4):1178-1184
pubmed: 28921658
Health Serv Res. 2003 Dec;38(6 Pt 1):1509-27
pubmed: 14727785
Popul Health Manag. 2018 Aug;21(4):296-302
pubmed: 29064345
Arthritis Care Res (Hoboken). 2017 Sep;69(9):1312-1321
pubmed: 28029753
J Ambul Care Manage. 2004 Jul-Sep;27(3):263-80
pubmed: 15287216

Auteurs

Adam J Rose (AJ)

RAND Corporation.
Section of General Internal Medicine, Boston University School of Medicine, Boston, MA.

Elizabeth Bayliss (E)

Institute for Health Research, Kaiser Permanente Colorado, Denver.
Department of Family Medicine, University of Colorado School of Medicine, Aurora, CO.

Lesley Baseman (L)

RAND Corporation, Arlington, VA.

Emily Butcher (E)

RAND Corporation.

Wenjing Huang (W)

RAND Corporation, Santa Monica, CA.

Maria O Edelen (MO)

RAND Corporation.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH